摘要
目的系统评价普拉克索治疗帕金森病（Pakinson＇s disease，PD）的临床疗效。方法通过检索Pubmed、Embase、Cochrane Database及中国生物医学文献数据库，检索国内外2007年4月前已发表的普拉克索对照安慰剂治疗PD的临床研究。对所纳入的研究进行质量评价及meta分析。结果共纳入10项随机对照试验（RCT）研究（纳入患者1738例），meta分析结果显示：普拉克索可以降低PD患者统一PD评分量表（UPDRS）总分[加权均数差值（WMD）=-10．01，95％CI（-12．76～-7．26）]、UPDRS Ⅱ分值[WMD=-2．44，95％CI（-2．93～-1．95）]以及UPDRS Ⅲ分值[WMD=-6．61，95％CI（-8．38～-4．84）]；普拉克索还可以降低晚期PD患者UPDRS Ⅳ分值[WMD=-0．73，95％CI（-1．16～-0．30）]，以上结果皆有统计学意义（P〈0．05）。3项研究比较了普拉克索与安慰剂治疗震颤的疗效，研究间存在异质性，其中2项研究显示疗效差异有统计学意义。结论普拉克索可以缓解患者的运动症状，改善生活质量。普拉克索具有改善治疗震颤的趋势，还需要更多的RCT研究进一步证实。
Objective To systemically evaluate the therapeutic effect of pramipexole in treating Parkinson＇ s disease. Methods Pubmed, Embase, Cechrane Database were used to search for randomized control trials （RCTs） on Parkinson＇ s disease treated with pramipexole. Meticulous data wre extracted and meta-analysis was performed according to a preset protocol. Results Ten RCTs involving 1738 patients were included. The results of meta-analysis showed that pramipexole decreased the total scores of unified Parkinson＇ s disease rating scale [ UPDRS, WMD = - 10.01,95% CI （ - 12. 76, - 7.26） ], UPDRS part Ⅱ [WMD= -2.44, 95%CI （ -2.93, -1.95）], and UPDRS part Ⅲ [WMD = -6.61, 95%CI （ -8.38, -4. 84）]. Pramipexole also reduced the score of UPDRS part Ⅳ [ WMD = -0. 73, 95% CI （ - 1.16, - 0. 30） ] in advanced patients （ P 〈 0. 05 ）. Three studies referred to the effect of pramipexole in treating parkinsonian tremor. However there was a clinical heterogeneity among the studies, and two of them revealed a significant difference. Conclusions Pramipexole might improve motor symptoms and the quality of life in advanced patients, as well as improve tremor, which needs more RCTs to be confirmed.
出处
《中华神经科杂志》
CAS
CSCD
北大核心
2008年第3期147-151,共5页
Chinese Journal of Neurology
基金
国家教育部留学回国人员基金资助项目（2006-331）
上海市教委发展基金资助项目（06BZ048）
上海市浦江人才计划资助项目
关键词
帕金森病
噻唑类
多巴胺激动剂
药物评价
Parkinson disease
Thiazoles
Dopamine agonists
Drug evaluation
